Compare · CGON vs RVMD
CGON vs RVMD
Side-by-side comparison of CG Oncology Inc. (CGON) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CGON and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $32.71B, about 6.2x CGON ($5.25B).
- Over the past year, CGON is up 134.1% and RVMD is up 287.6% - RVMD leads by 153.5 points.
- CGON has been more active in the news (10 items in the past 4 weeks vs 2 for RVMD).
- RVMD has more recent analyst coverage (25 ratings vs 16 for CGON).
- Company
- CG Oncology Inc.
- Revolution Medicines Inc.
- Price
- $59.59+3.41%
- $153.87+3.20%
- Market cap
- $5.25B
- $32.71B
- 1M return
- -19.51%
- +2.70%
- 1Y return
- +134.12%
- +287.58%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 2020
- News (4w)
- 10
- 2
- Recent ratings
- 16
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest CGON
- SEC Form 8-K filed by CG Oncology Inc.
- SEC Form 4 filed by Director Liu Brian Guan-Chyun
- SEC Form 4 filed by Director Tong Victor Edward Jr
- SEC Form 4 filed by Director Mulay James
- SEC Form 4 filed by Director Graf Susan E
- SEC Form 4 filed by Director Rossi Christina
- Director Post Leonard E exercised 1,000 shares at a strike of $0.60 and sold $54,500 worth of shares (1,000 units at $54.50) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by CG Oncology Inc.
- CG Oncology to Present at Upcoming Investor Conferences in June
- CG Oncology Inc. filed SEC Form 8-K: Leadership Update
Latest RVMD
- Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
- Officer Mancini Anthony exercised 3,121 shares at a strike of $33.62 and sold $480,611 worth of shares (3,121 units at $153.99) as part of a pre-agreed trading plan (SEC Form 4)
- Bernstein initiated coverage on Revolution Medicines with a new price target
- Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
- Truist resumed coverage on Revolution Medicines with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
- SEC Form 10-Q filed by Revolution Medicines Inc.
- Revolution Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress